Preparation and Evaluation of a Liposome Drug Delivery System in Cancer Treatment in vitro

IF 1.4 Q4 NANOSCIENCE & NANOTECHNOLOGY Journal of Nanostructures Pub Date : 2020-01-01 DOI:10.22052/JNS.2020.01.015

A. Akbari, A. Akbarzadeh, M. Tehrani, R. A. Cohan, A. Mozaffari, M. Memarzadeh

{"title":"Preparation and Evaluation of a Liposome Drug Delivery System in Cancer Treatment in vitro","authors":"A. Akbari, A. Akbarzadeh, M. Tehrani, R. A. Cohan, A. Mozaffari, M. Memarzadeh","doi":"10.22052/JNS.2020.01.015","DOIUrl":null,"url":null,"abstract":"Cancer is a fatal disease and relatively widespread in the world; Breast cancer is the most prevalent cancer among women. Hydroxyurea (HU) is a chemotherapy drug for the cure of cancer different types in patients, for example breast cancer, but has several defects, for to remove these problems in this study a nanoliposome (NL) suspension for Hydroxyurea (HU) delivery in breast cancer cell therapy was developed.HU was encapsulated into NLs. Size was measured by nanosizer. The release of the liposomal formulation was assessed during 36 h. FTIR analysis for liposomal Hydroxyurea and free Hydroxyurea was carried out. The uptake capacity of the formulation was determined by transfection of nanoliposomal hydroxyurea (NL-HU) in MDA-MB231 cells via flow cytometer and fluorescence microscopy studies, the cytotoxicity of NL-HU and free HU was evaluated in cells. Size of NL-HU was 174nm, HU encapsulation efficiencies in NLs was 81%. FTIR analysis showed the stability of HU in the liposome and no improper interaction between liposome and HU, release after 36h depicted sustained release behavior.NL-HU had suitable uptake in MDA-MB231 cells. Cytotoxicity of NL-HU on cells was considerable. We confirmed these nanoliposomes are potentially useful for delivery of Hydroxyurea in breast cancer cells treatment.","PeriodicalId":16523,"journal":{"name":"Journal of Nanostructures","volume":"10 1","pages":"140-147"},"PeriodicalIF":1.4000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Nanostructures","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22052/JNS.2020.01.015","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"NANOSCIENCE & NANOTECHNOLOGY","Score":null,"Total":0}

引用次数: 2

Abstract

Cancer is a fatal disease and relatively widespread in the world; Breast cancer is the most prevalent cancer among women. Hydroxyurea (HU) is a chemotherapy drug for the cure of cancer different types in patients, for example breast cancer, but has several defects, for to remove these problems in this study a nanoliposome (NL) suspension for Hydroxyurea (HU) delivery in breast cancer cell therapy was developed.HU was encapsulated into NLs. Size was measured by nanosizer. The release of the liposomal formulation was assessed during 36 h. FTIR analysis for liposomal Hydroxyurea and free Hydroxyurea was carried out. The uptake capacity of the formulation was determined by transfection of nanoliposomal hydroxyurea (NL-HU) in MDA-MB231 cells via flow cytometer and fluorescence microscopy studies, the cytotoxicity of NL-HU and free HU was evaluated in cells. Size of NL-HU was 174nm, HU encapsulation efficiencies in NLs was 81%. FTIR analysis showed the stability of HU in the liposome and no improper interaction between liposome and HU, release after 36h depicted sustained release behavior.NL-HU had suitable uptake in MDA-MB231 cells. Cytotoxicity of NL-HU on cells was considerable. We confirmed these nanoliposomes are potentially useful for delivery of Hydroxyurea in breast cancer cells treatment.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

脂质体给药系统的制备及体外肿瘤治疗评价

癌症是一种致命的疾病，在世界上比较普遍;乳腺癌是女性中最常见的癌症。羟基脲(HU)是一种治疗不同类型癌症的化疗药物，如乳腺癌，但存在一些缺陷，为了消除这些问题，本研究开发了一种用于羟基脲(HU)在乳腺癌细胞治疗中的纳米脂质体(NL)混悬液。HU被封装到NLs中。尺寸用纳米粒度仪测定。在36 h内评估脂质体制剂的释放度。对脂质体羟基脲和游离羟基脲进行FTIR分析。通过流式细胞仪和荧光显微镜观察转染纳米脂质体羟基脲(NL-HU)对MDA-MB231细胞的吸收能力，并对NL-HU和游离羟基脲的细胞毒性进行评价。NL-HU的尺寸为174nm, HU在NLs中的包封率为81%。FTIR分析表明，胡在脂质体中的稳定性较好，脂质体与胡无不良相互作用，36h后释放呈缓释行为。NL-HU在MDA-MB231细胞中有适当的摄取。NL-HU对细胞具有显著的细胞毒性。我们证实这些纳米脂质体在乳腺癌细胞治疗中对羟基脲的递送有潜在的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Nanostructures NANOSCIENCE & NANOTECHNOLOGY-

CiteScore

2.60

自引率

0.00%

发文量

审稿时长

7 weeks

期刊介绍： Journal of Nanostructures is a medium for global academics to exchange and disseminate their knowledge as well as the latest discoveries and advances in the science and engineering of nanostructured materials. Topics covered in the journal include, but are not limited to the following: Nanosystems for solar cell, energy, catalytic and environmental applications Quantum dots, nanocrystalline materials, nanoparticles, nanocomposites Characterization of nanostructures and size dependent properties Fullerenes, carbon nanotubes and graphene Self-assembly and molecular organization Super hydrophobic surface and material Synthesis of nanostructured materials Nanobiotechnology and nanomedicine Functionalization of nanostructures Nanomagnetics Nanosensors.